Number of the records: 1
BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas
- 1.0317969 - ÚMG 2009 RIV GB eng J - Journal Article
Reiniš, Milan
BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
[BiovaxID, individualizovaná vakcína proti B-buněčným lymfomům.]
Current Opinion in Molecular Therapeutics. Roč. 10, č. 5 (2008), s. 526-534. ISSN 1464-8431
Institutional research plan: CEZ:AV0Z50520514
Keywords : B-cell lymphomas * tumor antigen * therapeutic vaccine
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 2.913, year: 2008
Biovest International Inc (a subsidiary of Accentia BioPharmaceuticals Inc), under license from Stanford University, is developing BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas that, in combination with GM-CSF, exclusively targets cancerous B-cells by raising an immune response to tumor-specific immunoglobulin proteins called idiotypes, for the potential treatment of follicular non-Hodgkin’s lymphoma (NHL). Phase I and II clinical trials demonstrated the immunogenicity, safety and therapeutic efficacy of BiovaxID. Phase III clinical trials in NHL were ongoing at the time of publication.
Biovest International ( součást a subsidiary of Accentia BioPharmaceuticals Inc) vyvíjí podle licence ze Stanfordovy university BiovaxID, individualizovanou vakcínu proti B-buněčným lymfomům. Tato vakcína, v kombinaci s GM-CSF, vyvolává imunitní reakci proti nádorově-specifickým imunoglobulinům zvaným idiotypy a je vyvíjena pro léčbu non-Hodgkinových lymfomů. Klinické studie fáze I a II prokázaly imunogenicitu, bezpečnost a terapeutickou účinnost BiovaxIDu. Klinické studie fáze III probíhají.
Permanent Link: http://hdl.handle.net/11104/0167468
Number of the records: 1